We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Universal Health Grows Inorganically, Rising Costs a Drag
Read MoreHide Full Article
Universal Health Services, Inc.'s (UHS - Free Report) solid inorganic strategy positions it well for long-term growth. The acquisition of the adult services division of Cambian Group and Desert View Hospital in Nevada are worth a mention here.
The company’s top line has been growing consistently since 2006 except for 2012, driven primarily by solid inorganic growth and strong performance from both of its segments — Acute Care and Behavioral Health.
Its acute care platform has been delivering strong underwriting results consistently. The same trend continued in the first nine months of 2017 as well.
In addition, its behavioral platform has been performing well too. In fact, behavioral facility acquisitions help Universal Health win market share in the fast growing addiction and mental health disorder market. The segment continued to deliver strong results in the first nine months of 2017.
Month to date, shares of Universal Health have gained 5.6% while the industry has rallied 4.9%.
However, the stock is currently trading at a trailing 12-month price-to-earnings ratio of 15.3, which is at its median range, the same compares unfavorably with the industry average of 14.9. This suggests that the stock is overvalued compared to its peers.
In addition, the company’s high-debt level has been a concern over the last few years. This also led to a rise in interest expenses which has been putting pressure on its margins.
Another area of concern for the company is the increase in its operating expenses since 2013, which continued to rise in the first nine months of 2017. This also keeps weighing on the company’s bottom line.
Zacks Rank & Stocks to Consider
Universal Health currently has a Zacks Rank #3 (Hold).
Align Technology delivered positive surprises in each of the last four quarters, with an average beat of 16.6%.
Amedisys delivered positive surprises in each of the last four quarters, with an average beat of 13.1%.
Cerus Corp delivered positive surprises in three of the last four quarters, with an average beat of 7.8%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Universal Health Grows Inorganically, Rising Costs a Drag
Universal Health Services, Inc.'s (UHS - Free Report) solid inorganic strategy positions it well for long-term growth. The acquisition of the adult services division of Cambian Group and Desert View Hospital in Nevada are worth a mention here.
The company’s top line has been growing consistently since 2006 except for 2012, driven primarily by solid inorganic growth and strong performance from both of its segments — Acute Care and Behavioral Health.
Its acute care platform has been delivering strong underwriting results consistently. The same trend continued in the first nine months of 2017 as well.
In addition, its behavioral platform has been performing well too. In fact, behavioral facility acquisitions help Universal Health win market share in the fast growing addiction and mental health disorder market. The segment continued to deliver strong results in the first nine months of 2017.
Month to date, shares of Universal Health have gained 5.6% while the industry has rallied 4.9%.
However, the stock is currently trading at a trailing 12-month price-to-earnings ratio of 15.3, which is at its median range, the same compares unfavorably with the industry average of 14.9. This suggests that the stock is overvalued compared to its peers.
In addition, the company’s high-debt level has been a concern over the last few years. This also led to a rise in interest expenses which has been putting pressure on its margins.
Another area of concern for the company is the increase in its operating expenses since 2013, which continued to rise in the first nine months of 2017. This also keeps weighing on the company’s bottom line.
Zacks Rank & Stocks to Consider
Universal Health currently has a Zacks Rank #3 (Hold).
Investors interested in the medical sector can consider some better-ranked stocks like Align Technology, Inc. (ALGN - Free Report) , Amedisys, Inc. (AMED - Free Report) and Cerus Corporation (CERS - Free Report) . While Align Technology sports a Zacks Rank #1 (Strong Buy), the other two stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology delivered positive surprises in each of the last four quarters, with an average beat of 16.6%.
Amedisys delivered positive surprises in each of the last four quarters, with an average beat of 13.1%.
Cerus Corp delivered positive surprises in three of the last four quarters, with an average beat of 7.8%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>